ArticleMedicine2026
Prognostic value of the hyperdense middle cerebral artery sign in patients undergoing mechanical thrombectomy.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hyperdense middle cerebral artery sign (HMCAS) is a well-established computed tomography marker of arterial thrombus in acute ischemic stroke (AIS); however, its prognostic value in the modern mechanical thrombectomy (MT) era remains uncertain. This study aimed to evaluate whether HMCAS predicts recanalization success, functional outcome, and hemorrhagic transformation (HT) following MT. We retrospectively analyzed 149 patients with anterior circulation large vessel occlusion who underwent MT between May 2018 and July 2023. Clinical, imaging, and procedural parameters were compared between patients with and without HMCAS on baseline non-contrast computed tomography. The primary outcomes were successful recanalization, defined as modified thrombolysis in cerebral infarction (mTICI) 2b-3, and favorable 90-day functional outcome, defined as a modified Rankin Scale score of 2 or less. Secondary outcomes included HT and mortality. HMCAS was identified in 101 patients (67.8%). Patients with HMCAS were older (73.4 ± 12.2 vs 68.7 ± 14.2 years, P = .039) and had a higher prevalence of diabetes mellitus (39.5% vs 21.4%, P = .047). Baseline National Institutes of Health Stroke Scale scores were lower in the HMCAS group (median, 13 vs 15.5, P = .005). There were no significant differences between the groups in successful recanalization, functional independence, or mortality (P > .05 for all). However, HMCAS was significantly associated with HT (P < .001). In multivariable analysis, clot length (odds ratio [OR] = 1.10, P = .043) and shorter procedure duration (OR = 0.98, P = .003) independently predicted successful recanalization, whereas older age (OR = 0.96, P = .028), lower Alberta Stroke Program Early CT Score, HT (OR = 0.67, P = .003), and a higher number of passes (OR = 0.61, P = .024) predicted poor functional outcome. HMCAS was not an independent predictor of successful recanalization or favorable 90-day functional outcome after MT, but it was significantly associated with hemorrhagic transformation, suggesting that its presence on baseline non-contrast computed tomography may warrant closer periprocedural attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.